Apogee Therapeutics, Inc.
APGE
$68.50
$1.732.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -6.71% | 1.63% | -19.44% | 17.67% | -37.13% |
| Total Depreciation and Amortization | 0.00% | 1.75% | 92.75% | 172.37% | 58.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -0.45% | 6.59% | 9.38% | 78.38% | 97.87% |
| Change in Net Operating Assets | -480.05% | 87.76% | -131.84% | 50.49% | -259.89% |
| Cash from Operations | -15.55% | 12.53% | -27.96% | 28.41% | -59.24% |
| Capital Expenditure | -- | 100.00% | 82.21% | -431,800.00% | 100.13% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,708.05% | -77.25% | 356.06% | -62.69% | 131.84% |
| Cash from Investing | -1,708.39% | -77.03% | 501.79% | -72.00% | 131.68% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,799.64% | 1,572.71% | 89.71% | -98.60% | 11,481.20% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,799.64% | 1,572.71% | 89.71% | -98.60% | 11,481.20% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 242.62% | -195.92% | 149.54% | -251.56% | 112.21% |